PMC:7054527 / 4974-6327 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T22","span":{"begin":70,"end":77},"obj":"Body_part"},{"id":"T23","span":{"begin":175,"end":183},"obj":"Body_part"},{"id":"T24","span":{"begin":193,"end":196},"obj":"Body_part"},{"id":"T25","span":{"begin":271,"end":283},"obj":"Body_part"},{"id":"T26","span":{"begin":323,"end":330},"obj":"Body_part"},{"id":"T27","span":{"begin":460,"end":470},"obj":"Body_part"},{"id":"T28","span":{"begin":487,"end":494},"obj":"Body_part"},{"id":"T29","span":{"begin":693,"end":698},"obj":"Body_part"},{"id":"T30","span":{"begin":762,"end":767},"obj":"Body_part"},{"id":"T31","span":{"begin":812,"end":820},"obj":"Body_part"},{"id":"T32","span":{"begin":859,"end":867},"obj":"Body_part"},{"id":"T33","span":{"begin":877,"end":882},"obj":"Body_part"},{"id":"T34","span":{"begin":1065,"end":1072},"obj":"Body_part"},{"id":"T35","span":{"begin":1197,"end":1203},"obj":"Body_part"},{"id":"T36","span":{"begin":1247,"end":1254},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma82739"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma82764"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"2019-nCoV possessed the typical coronavirus structure with the “spike protein” in the membrane envelope30, and also expressed other polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins10,11,30. The S protein from coronavirus can bind to the receptors of the host to facilitate viral entry into target cells31,32. Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensin-converting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV36–39. The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV40,41. The cellular serine protease TMPRSS2 also contributed to the S-protein priming of 2019-nCoV, indicating that the TMPRSS2 inhibitor might constitute a treatment option36."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":877,"end":882},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"2019-nCoV possessed the typical coronavirus structure with the “spike protein” in the membrane envelope30, and also expressed other polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins10,11,30. The S protein from coronavirus can bind to the receptors of the host to facilitate viral entry into target cells31,32. Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensin-converting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV36–39. The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV40,41. The cellular serine protease TMPRSS2 also contributed to the S-protein priming of 2019-nCoV, indicating that the TMPRSS2 inhibitor might constitute a treatment option36."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T39","span":{"begin":517,"end":525},"obj":"Disease"},{"id":"T40","span":{"begin":517,"end":521},"obj":"Disease"},{"id":"T41","span":{"begin":631,"end":639},"obj":"Disease"},{"id":"T42","span":{"begin":631,"end":635},"obj":"Disease"},{"id":"T43","span":{"begin":824,"end":832},"obj":"Disease"},{"id":"T44","span":{"begin":824,"end":828},"obj":"Disease"},{"id":"T45","span":{"begin":903,"end":911},"obj":"Disease"},{"id":"T46","span":{"begin":903,"end":907},"obj":"Disease"}],"attributes":[{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"2019-nCoV possessed the typical coronavirus structure with the “spike protein” in the membrane envelope30, and also expressed other polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins10,11,30. The S protein from coronavirus can bind to the receptors of the host to facilitate viral entry into target cells31,32. Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensin-converting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV36–39. The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV40,41. The cellular serine protease TMPRSS2 also contributed to the S-protein priming of 2019-nCoV, indicating that the TMPRSS2 inhibitor might constitute a treatment option36."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T43","span":{"begin":86,"end":94},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T44","span":{"begin":166,"end":174},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T45","span":{"begin":558,"end":563},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T46","span":{"begin":693,"end":698},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T47","span":{"begin":704,"end":709},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T48","span":{"begin":711,"end":714},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"},{"id":"T49","span":{"begin":762,"end":767},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T50","span":{"begin":786,"end":788},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T51","span":{"begin":790,"end":791},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T52","span":{"begin":822,"end":823},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T53","span":{"begin":842,"end":847},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T54","span":{"begin":888,"end":889},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T55","span":{"begin":1332,"end":1333},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"2019-nCoV possessed the typical coronavirus structure with the “spike protein” in the membrane envelope30, and also expressed other polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins10,11,30. The S protein from coronavirus can bind to the receptors of the host to facilitate viral entry into target cells31,32. Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensin-converting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV36–39. The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV40,41. The cellular serine protease TMPRSS2 also contributed to the S-protein priming of 2019-nCoV, indicating that the TMPRSS2 inhibitor might constitute a treatment option36."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":70,"end":77},"obj":"Chemical"},{"id":"T6","span":{"begin":175,"end":183},"obj":"Chemical"},{"id":"T7","span":{"begin":271,"end":283},"obj":"Chemical"},{"id":"T8","span":{"begin":323,"end":330},"obj":"Chemical"},{"id":"T9","span":{"begin":460,"end":470},"obj":"Chemical"},{"id":"T10","span":{"begin":460,"end":465},"obj":"Chemical"},{"id":"T11","span":{"begin":466,"end":470},"obj":"Chemical"},{"id":"T12","span":{"begin":487,"end":494},"obj":"Chemical"},{"id":"T13","span":{"begin":564,"end":575},"obj":"Chemical"},{"id":"T14","span":{"begin":722,"end":725},"obj":"Chemical"},{"id":"T15","span":{"begin":1065,"end":1072},"obj":"Chemical"},{"id":"T16","span":{"begin":1197,"end":1203},"obj":"Chemical"},{"id":"T17","span":{"begin":1247,"end":1254},"obj":"Chemical"},{"id":"T18","span":{"begin":1305,"end":1314},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_32402"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_17822"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"2019-nCoV possessed the typical coronavirus structure with the “spike protein” in the membrane envelope30, and also expressed other polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins10,11,30. The S protein from coronavirus can bind to the receptors of the host to facilitate viral entry into target cells31,32. Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensin-converting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV36–39. The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV40,41. The cellular serine protease TMPRSS2 also contributed to the S-protein priming of 2019-nCoV, indicating that the TMPRSS2 inhibitor might constitute a treatment option36."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T34","span":{"begin":0,"end":316},"obj":"Sentence"},{"id":"T35","span":{"begin":317,"end":435},"obj":"Sentence"},{"id":"T36","span":{"begin":436,"end":789},"obj":"Sentence"},{"id":"T37","span":{"begin":790,"end":1017},"obj":"Sentence"},{"id":"T38","span":{"begin":1018,"end":1183},"obj":"Sentence"},{"id":"T39","span":{"begin":1184,"end":1353},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"2019-nCoV possessed the typical coronavirus structure with the “spike protein” in the membrane envelope30, and also expressed other polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins10,11,30. The S protein from coronavirus can bind to the receptors of the host to facilitate viral entry into target cells31,32. Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensin-converting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV36–39. The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV40,41. The cellular serine protease TMPRSS2 also contributed to the S-protein priming of 2019-nCoV, indicating that the TMPRSS2 inhibitor might constitute a treatment option36."}

2_test

{"project":"2_test","denotations":[{"id":"32127517-27578435-53455635","span":{"begin":103,"end":105},"obj":"27578435"},{"id":"32127517-27578435-53455636","span":{"begin":313,"end":315},"obj":"27578435"},{"id":"32127517-30567993-53455637","span":{"begin":429,"end":431},"obj":"30567993"},{"id":"32127517-22816037-53455638","span":{"begin":432,"end":434},"obj":"22816037"},{"id":"32127517-32065055-53455639","span":{"begin":1011,"end":1013},"obj":"32065055"},{"id":"T63019","span":{"begin":103,"end":105},"obj":"27578435"},{"id":"T4951","span":{"begin":313,"end":315},"obj":"27578435"},{"id":"T6721","span":{"begin":429,"end":431},"obj":"30567993"},{"id":"T53119","span":{"begin":432,"end":434},"obj":"22816037"},{"id":"T24045","span":{"begin":1011,"end":1013},"obj":"32065055"}],"text":"2019-nCoV possessed the typical coronavirus structure with the “spike protein” in the membrane envelope30, and also expressed other polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins10,11,30. The S protein from coronavirus can bind to the receptors of the host to facilitate viral entry into target cells31,32. Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensin-converting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV36–39. The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV40,41. The cellular serine protease TMPRSS2 also contributed to the S-protein priming of 2019-nCoV, indicating that the TMPRSS2 inhibitor might constitute a treatment option36."}

PMC:7054527 / 4974-6327 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7054527 / 4974-6327 JSON TXT